Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Annie Killoran"'
Autor:
Aldo A. Mendez, Annaliese Bosco, Lama Abdel-Wahed, Kendra Palmer, Karra A. Jones, Annie Killoran
Publikováno v:
Case Reports in Neurology, Vol 10, Iss 2, Pp 217-222 (2018)
An 88-year-old man presented with a 1-month history of altered mental status and seizures. His electrographic and imaging findings were suggestive of herpes simplex encephalitis (HSE), for which he was empirically treated with acyclovir. He underwent
Externí odkaz:
https://doaj.org/article/a01ad1fbbd474824bdcfe1e8b128aa97
Autor:
Annie Killoran
Publikováno v:
Neurodegenerative Diseases Biomarkers ISBN: 9781071617113
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78ad9d9f1520729a06bff03896f7b1de
https://doi.org/10.1007/978-1-0716-1712-0_10
https://doi.org/10.1007/978-1-0716-1712-0_10
Publikováno v:
Movement Disorders Clinical Practice. 6:132-138
Introduction Huntington's chorea (HC) is commonly managed with neuroleptic medications, though there is little evidence to support their use. This study aimed to perform a real-world comparison of the efficacy of risperidone and olanzapine to tetrabe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5296f209f49d14cbc6121b0cbf39ab
https://doi.org/10.1002/mdc3.12706
https://doi.org/10.1002/mdc3.12706
Autor:
Karra A. Jones, Aldo A Mendez, Annaliese Bosco, Lama Abdel-Wahed, Kendra L. Palmer, Annie Killoran
Publikováno v:
Case Reports in Neurology, Vol 10, Iss 2, Pp 217-222 (2018)
Case Reports in Neurology
Case Reports in Neurology
An 88-year-old man presented with a 1-month history of altered mental status and seizures. His electrographic and imaging findings were suggestive of herpes simplex encephalitis (HSE), for which he was empirically treated with acyclovir. He underwent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fed1d37e75d96f6e1a9636bf1a741f54
https://www.karger.com/Article/FullText/492053
https://www.karger.com/Article/FullText/492053
Autor:
Annie Killoran, John Kamholz, David J. Moser, Peg Nopoulos, Chloe C. Chabal, Jordan L. Schultz
Publikováno v:
Neurology. 91:e202-e207
ObjectiveTo determine whether tetrabenazine (TBZ) use is associated with an increased incidence of depression and/or suicidal ideation.MethodsIn this retrospective cross-sectional study of the Enroll-HD database, we used multiple logistic regression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb517ac64147fc2d060ad13fda59e719
https://doi.org/10.1212/wnl.0000000000005817
https://doi.org/10.1212/wnl.0000000000005817
Publikováno v:
Neurology. 92(9)
We thank Sampaio et al. for the comment on our article.1 The Enroll-HD dataset does not contain information regarding why participants abandoned a particular therapy.2 Therefore, making the assumption that abandonment of tetrabenazine (TBZ) therapy o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c9c648e050f91e21563c54a9636021d
https://pubmed.ncbi.nlm.nih.gov/30804061
https://pubmed.ncbi.nlm.nih.gov/30804061
Publikováno v:
Movement disorders 34(5), 762-763 (2019). doi:10.1002/mds.27680
Mov Disord
Mov Disord
Background There is evidence to suggest that 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) may be beneficial in Huntington's disease (HD). Objective This study aimed to determine if statin use was associated with delayed motor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::651e8184363d9ffc6f179f59a0968531
https://pubmed.ncbi.nlm.nih.gov/31091360
https://pubmed.ncbi.nlm.nih.gov/31091360
Publikováno v:
Movement Disorders. 34:763-764
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a35e08db823bc80f9feb0b2c459fa0a
https://doi.org/10.1002/mds.27678
https://doi.org/10.1002/mds.27678
Autor:
Annie Killoran, Kevin M. Biglan
Publikováno v:
Movement Disorders. 29:1404-1413
Therapeutic decision-making in Huntington's disease (HD) is often guided by clinical experience, because of the limited empirical evidence available. The only medication for HD that has met the regulatory hurdle for approval is tetrabenazine, indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::979756fbc32e6efd709e3c01518674a0
https://doi.org/10.1002/mds.26014
https://doi.org/10.1002/mds.26014
Autor:
Kevin M. Biglan, Shirley Eberly, David Oakes, Joseph Jankovic, Anne B. Young, Elise Kayson, Annie Killoran, Ira Shoulson
Publikováno v:
Neurology. 80:2022-2027
Objectives: We aimed to describe the clinical phenotype conferred by the intermediate-length huntingtin allele CAG repeat expansion in a population-based study. Methods: The Prospective Huntington At Risk Observational Study (PHAROS) enrolled adults
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9521d5e2d4886e778a326601d8e917d
https://doi.org/10.1212/wnl.0b013e318294b304
https://doi.org/10.1212/wnl.0b013e318294b304